Days ahead of Prime Minister Atal Bihari Vajpayee's visit to China accompanied by a 55-member industry delegation, CII on Monday said the country provided ample business opportunities and incentives in sectors like IT, drugs and pharmaceuticals and biotechnology.
According to a survey
conducted by CII on knowledge-based industries like IT, biotech and drugs and pharmaceuticals, there were enough reasons for the domestic industry to look east which included incentives for investment like reduction in local and national taxes, land rentals and import and export duties.
With the IT products and application consumption in the SMEs in China expected to touch $12 billion this year, an increase of 23 per cent from 2001, and 27 $billion in 2006, the domestic IT industry has a huge market to tap, CII said in a statement.
In the drugs and pharmaceuticals sector, China is likely to emerge as the fifth largest market globally by 2010 with revenues of over $24 billion, more than triple its current size.
"Such growth would catapult China's market, which currently ranks seventh, to a position right behind the drug markets of France and Germany. Driving this growth are China's ongoing economic development and its recent entry into the WTO," CII said in its survey.
The most promising opportunities are expected to be in the areas of innovative ethical or prescription, drugs and differentiated over-the-counter (OTC) products. The market for ethical drugs would climb to $19 billion by 2010, it said.